- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02612610
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
June 17, 2020 updated by: Afferent Pharmaceuticals, Inc.
A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough
This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency.
The primary hypothesis for this trial is that at least one dose regimen of gefapixant is superior to placebo with respect to the mean change from baseline in awake cough frequency (on the log scale).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
253
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Women and Men between 18 and 80 years of age inclusive
- Have refractory chronic cough
- Women of child-bearing potential must use 2 forms of acceptable birth control - Have provided written informed consent.
- Are willing and able to comply with all aspects of the protocol
Exclusion Criteria:
- Current smoker
- Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio <60%
- History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit
- History of opioid use within 1 week of the Baseline Visit
- Body mass index (BMI) <18 kg/m^2 or ≥ 40 kg/m^2
- History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with <3 excised basal cell carcinomas)
- Screening systolic blood pressure (SBP) >160 mm Hg or a diastolic blood pressure (DBP) >90 mm Hg
- Clinically significant abnormal electrocardiogram (ECG) at Screening
- Significantly abnormal laboratory tests at Screening
- Pregnant or Breastfeeding
- Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the participant inappropriate for entry into this trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
|
Other Names:
|
Experimental: Gefapixant 7.5 mg
Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
|
Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
Other Names:
|
Experimental: Gefapixant 20 mg
Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
|
Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
Other Names:
|
Experimental: Gefapixant 50 mg
Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
|
Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Awake Objective Cough Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline Visit (Day -1), Day 84
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 12 (Day 84) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
Least-squares (LS) mean change from baseline (in log scale) with associated standard error (SE) reported for each treatment group.
Change from Baseline in Awake Objective Cough Frequency = (Post-Treatment Awake Cough Frequency minus Baseline Awake Cough Frequency).
|
Baseline Visit (Day -1), Day 84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in 24-Hour Objective Cough Frequency After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 4 (Day 28) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in 24-Hour Objective Cough Frequency = (Post-Treatment 24-Hour Cough Frequency minus Baseline 24-Hour Cough Frequency).
|
Baseline (Study Day -1), Day 28
|
Change From Baseline in 24-Hour Objective Cough Frequency After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 8 (Day 56) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in 24-Hour Objective Cough Frequency = (Post-Treatment 24-Hour Cough Frequency minus Baseline 24-Hour Cough Frequency).
|
Baseline (Study Day -1), Day 56
|
Change From Baseline in 24-Hour Objective Cough Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline (Study Day -1), Day 84
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 12 (Day 84) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in 24-Hour Objective Cough Frequency = (Post-Treatment 24-Hour Cough Frequency minus Baseline 24-Hour Cough Frequency).
|
Baseline (Study Day -1), Day 84
|
Change From Baseline in Awake Objective Cough Frequency After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28,
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 4 (Day 28) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in Awake Objective Cough Frequency = (Post-Treatment Awake Cough Frequency minus Baseline Awake Cough Frequency).
|
Baseline (Study Day -1), Day 28,
|
Change From Baseline in Awake Objective Cough Frequency After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 8 (Day 56) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in Awake Objective Cough Frequency = (Post-Treatment Awake Cough Frequency minus Baseline Awake Cough Frequency).
|
Baseline (Study Day -1), Day 56
|
Change From Baseline in Awake Objective Cough Frequency at the Follow-up Visit (Day 98)
Time Frame: Baseline (Study Day -1), Day 98
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at the Follow-up visit (Day 98) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
Change from Baseline in Awake Objective Cough Frequency = (Post-Treatment Awake Cough Frequency minus Baseline Awake Cough Frequency).
|
Baseline (Study Day -1), Day 98
|
Change From Baseline in Cough Severity Visual Analogue Scale (VAS) After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28
|
Cough VAS was scored from 0 to 100 using a 100 mm visual analogue scale.
Participants were asked to mark on a 100 mm scale between 0 (no cough) and 100 (the worst cough severity).
Cough VAS was evaluated at Baseline (Study Day -1) and at Week 4 (Day 28).
Baseline cough VAS was defined as the cough VAS at Baseline (Study Day -1).
LS mean change from baseline with associated SE reported for each treatment group.
|
Baseline (Study Day -1), Day 28
|
Change From Baseline in Cough Severity VAS After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
Cough VAS was scored from 0 to 100 using a 100 mm visual analogue scale.
Participants were asked to mark on a 100 mm scale between 0 (no cough) and 100 (the worst cough severity).
Cough VAS was evaluated at Baseline (Study Day -1) and at Week 8 (Day 56).
Baseline cough VAS was defined as the cough VAS at Baseline (Study Day -1).
LS mean change from baseline with associated SE reported for each treatment group.
|
Baseline (Study Day -1), Day 56
|
Change From Baseline in Cough Severity VAS After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline (Study Day -1), Day 84
|
Cough VAS was scored from 0 to 100 using a 100 mm visual analogue scale.
Participants were asked to mark on a 100 mm scale between 0 (no cough) and 100 (the worst cough severity).
Cough VAS was evaluated at Baseline (Study Day -1) and at Week 12 (Day 84).
Baseline cough VAS was defined as the cough VAS at Baseline (Study Day -1).
LS mean change from baseline with associated SE reported for each treatment group.
|
Baseline (Study Day -1), Day 84
|
Change From Baseline in Cough Severity VAS At Day 85/Early Termination
Time Frame: Baseline (Study Day -1), Day 85
|
Cough VAS was scored from 0 to 100 using a 100 mm visual analogue scale.
Participants were asked to mark on a 100 mm scale between 0 (no cough) and 100 (the worst cough severity).
Cough VAS was evaluated at Baseline (Study Day -1) and at Day 85/Early Termination.
Baseline cough VAS was defined as the cough VAS at Baseline (Study Day -1).
LS mean change from baseline with associated SE reported for each treatment group.
|
Baseline (Study Day -1), Day 85
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in Awake Objective Cough Frequency After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 4 (Day 28) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in Awake Objective Cough Frequency were reported for each treatment group at Day 28.
|
Baseline (Study Day -1), Day 28
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in Awake Objective Cough Frequency After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 8 (Day 56) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in Awake Objective Cough Frequency were reported for each treatment group at Day 56.
|
Baseline (Study Day -1), Day 56
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in Awake Objective Cough Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline (Study Day -1), Day 84
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 12 (Day 84) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in Awake Objective Cough Frequency were reported for each treatment group at Day 84.
|
Baseline (Study Day -1), Day 84
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in Awake Objective Cough Frequency at the Follow-up Visit (Day 98)
Time Frame: Baseline (Study Day -1), Day 98
|
Awake Objective Cough Frequency (per hour) was defined as the total number of cough events during the monitoring period (in general, 24-hr interval) while the participant was awake divided by the total duration (in hours) for the monitoring period that the participant was awake.
24 hour sound recordings were made at Baseline (Study Day -1) and at the Follow-up visit (Day 98) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in Awake Objective Cough Frequency were reported for each treatment group at Day 98.
|
Baseline (Study Day -1), Day 98
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in 24-Hour Objective Cough Frequency After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 4 (Day 28) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in 24-hr Objective Cough Frequency were reported for each treatment group at Day 28.
|
Baseline (Study Day -1), Day 28
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in 24-Hour Objective Cough Frequency After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 8 (Day 56) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in 24-hr Objective Cough Frequency were reported for each treatment group at Day 56.
|
Baseline (Study Day -1), Day 56
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in 24-Hour Objective Cough Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline (Study Day -1), Day 84
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 12 (Day 84) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in 24-hr Objective Cough Frequency were reported for each treatment group at Day 84.
|
Baseline (Study Day -1), Day 84
|
Percentage of Participants With ≥70%, ≥50%, and ≥30% Change From Baseline in 24-Hour Objective Cough Frequency at the Follow-up Visit (Day 98)
Time Frame: Baseline (Study Day -1), Day 98
|
24-hr Objective Cough Frequency was defined as the total number of cough events during the monitoring period divided by the total duration in hours for the monitoring period (generally 24 hours).
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 14 (Day 98) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
The percentage of participants that met responder criteria for ≥70%, ≥50%, and ≥30% change (reduction) from baseline levels in 24-hr Objective Cough Frequency were reported for each treatment group at Day 98.
|
Baseline (Study Day -1), Day 98
|
Change From Baseline in Sleep Objective Cough Frequency After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline (Study Day -1), Day 28
|
Sleep Objective Cough Frequency was defined as the total number of cough events during the monitoring period while the participant was asleep divided by the total duration in hours for the monitoring period that the participant was asleep.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 4 (Day 28) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in Sleep Objective Cough Frequency = (Post-Treatment Objective Sleep Cough Frequency minus Baseline Sleep Cough Frequency).
|
Baseline (Study Day -1), Day 28
|
Change From Baseline in Sleep Objective Cough Frequency After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline (Study Day -1), Day 56
|
Sleep Objective Cough Frequency was defined as the total number of cough events during the monitoring period while the participant was asleep divided by the total duration in hours for the monitoring period that the participant was asleep.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 8 (Day 56) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in Sleep Objective Cough Frequency = (Post-Treatment Objective Sleep Cough Frequency minus Baseline Sleep Cough Frequency).
|
Baseline (Study Day -1), Day 56
|
Change From Baseline in Sleep Objective Cough Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Baseline (Study Day -1), Day 84
|
Sleep Objective Cough Frequency was defined as the total number of cough events during the monitoring period while the participant was asleep divided by the total duration in hours for the monitoring period that the participant was asleep.
24 hour sound recordings were made at Baseline (Study Day -1) and at Week 12 (Day 84) using a digital recording device.
An independent cough monitoring center documented the time of each cough event over the 24 hour period, as well as the time when the participant went to sleep and the time the participant woke.
LS mean change from baseline (in log scale) with associated SE reported for each treatment group.
Change from Baseline in Sleep Objective Cough Frequency = (Post-Treatment Objective Sleep Cough Frequency minus Baseline Sleep Cough Frequency).
|
Baseline (Study Day -1), Day 84
|
Change From Baseline in Weekly Mean Daily Cough Severity Diary (CSD) Total Score at Week 1
Time Frame: Baseline, Week 1
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 1
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 2
Time Frame: Baseline, Week 2
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 2
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 3
Time Frame: Baseline, Week 3
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 3
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 4
Time Frame: Baseline, Week 4
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 4
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 5
Time Frame: Baseline, Week 5
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 5
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 6
Time Frame: Baseline, Week 6
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 6
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 7
Time Frame: Baseline, Week 7
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 7
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 8
Time Frame: Baseline, Week 8
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 8
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 9
Time Frame: Baseline, Week 9
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 9
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 10
Time Frame: Baseline, Week 10
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 10
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 11
Time Frame: Baseline, Week 11
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 11
|
Change From Baseline in Weekly Mean Daily CSD Total Score at Week 12
Time Frame: Baseline, Week 12
|
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 (worst).
The total daily CSD is the sum of these 7 item scores (Min=0, Max=70).
Mean total daily score (the sum of 7 item scores divided by 7) was derived for each day.
Weekly mean total daily score was defined as the average of the mean total daily scores for each week.
LS mean change from baseline of the weekly mean total daily CSD score was reported for each treatment group with associated SE.
Baseline was defined as the average CSD scores collected during the week prior to Day 1 (Study Day -7 to Day -1).
|
Baseline, Week 12
|
Change From Baseline in Weekly Mean Daily Cough Score (DCS) at Week 1
Time Frame: Baseline, Week 1
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 1
|
Change From Baseline in Weekly Mean DCS at Week 2
Time Frame: Baseline, Week 2
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 2
|
Change From Baseline in Weekly Mean DCS at Week 3
Time Frame: Baseline, Week 3
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 3
|
Change From Baseline in Weekly Mean DCS at Week 4
Time Frame: Baseline, Week 4
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 4
|
Change From Baseline in Weekly Mean DCS at Week 5
Time Frame: Baseline, Week 5
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 5
|
Change From Baseline in Weekly Mean DCS at Week 6
Time Frame: Baseline, Week 6
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 6
|
Change From Baseline in Weekly Mean DCS at Week 7
Time Frame: Baseline, Week 7
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 7
|
Change From Baseline in Weekly Mean DCS at Week 8
Time Frame: Baseline, Week 8
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 8
|
Change From Baseline in Weekly Mean DCS at Week 9
Time Frame: Baseline, Week 9
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 9
|
Change From Baseline in Weekly Mean DCS at Week 10
Time Frame: Baseline, Week 10
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 10
|
Change From Baseline in Weekly Mean DCS at Week 11
Time Frame: Baseline, Week 11
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 11
|
Change From Baseline in Weekly Mean DCS at Week 12
Time Frame: Baseline, Week 12
|
The DCS has a score ranging from 0 (best) to 10 (worst).
Weekly mean daily score was defined as the average of the daily scores for each week.
Baseline was defined as the average DCS score collected during the week prior to Day 1 (Day -7 to Day -1).
Participants rated the severity of their cough using the DCS each day.
LS mean change from baseline of the weekly mean Daily Cough Score with associated SE was reported for each treatment group.
|
Baseline, Week 12
|
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score After 4 Weeks of Treatment (Day 28)
Time Frame: Baseline, Day 28
|
The LCQ instrument is designed to assess the impact of cough on various aspects of a participant's life over the preceding 2 weeks.
It consists of 19 items which are divided over 3 domains: Physical (items 1, 2, 3, 9, 10, 11, 14 and 15), Psychological (4, 5, 6, 12, 13, 16, and 17), and Social (7, 8, 18, 19).
A 7-point Likert scale is used to rate each item.
For each domain, the domain score (range 1-7) is the sum of the individual item scores within the domain divided by the number of items in the domain.
The total score is the sum of the three domain scores and ranges from 3-21; a higher score corresponds to a better health status.
Baseline LCQ was defined as the LCQ collected at Baseline (Study Day -1).
LS mean change from baseline in total LCQ score was reported for each treatment group with associated SE.
|
Baseline, Day 28
|
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score After 8 Weeks of Treatment (Day 56)
Time Frame: Baseline, Day 56
|
The LCQ instrument is designed to assess the impact of cough on various aspects of a participant's life over the preceding 2 weeks.
It consists of 19 items which are divided over 3 domains: Physical (items 1, 2, 3, 9, 10, 11, 14 and 15), Psychological (4, 5, 6, 12, 13, 16, and 17), and Social (7, 8, 18, 19).
A 7-point Likert scale is used to rate each item.
For each domain, the domain score (range 1-7) is the sum of the individual item scores within the domain divided by the number of items in the domain.
The total score is the sum of the three domain scores and ranges from 3-21; a higher score corresponds to a better health status.
Baseline LCQ was defined as the LCQ collected at Baseline (Study Day -1).
LS mean change from baseline in total LCQ score was reported for each treatment group with associated SE.
|
Baseline, Day 56
|
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score At Day 85/Early Termination
Time Frame: Baseline, Day 85/Early Termination
|
The LCQ instrument is designed to assess the impact of cough on various aspects of a participant's life over the preceding 2 weeks.
It consists of 19 items which are divided over 3 domains: Physical (items 1, 2, 3, 9, 10, 11, 14 and 15), Psychological (4, 5, 6, 12, 13, 16, and 17), and Social (7, 8, 18, 19).
A 7-point Likert scale is used to rate each item.
For each domain, the domain score (range 1-7) is the sum of the individual item scores within the domain divided by the number of items in the domain.
The total score is the sum of the three domain scores and ranges from 3-21; a higher score corresponds to a better health status.
Baseline LCQ was defined as the LCQ collected at Baseline (Study Day -1).
LS mean change from baseline in total LCQ score was reported for each treatment group with associated SE.
|
Baseline, Day 85/Early Termination
|
Percentage of Participants Reporting "Very Much Improved" or "Much Improved" According to the Patient's Global Impression of Change (PGIC) After 4 Weeks of Treatment (Day 28)
Time Frame: Day 28
|
The self-reported measure Patient's Global Impression of Change (PGIC) reflects a participant's belief about the efficacy of treatment.
PGIC is a 7-point scale depicting a patient's rating of overall improvement.
Participants rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
The counts and percentages of ordered responses to the participant's global perception of change were computed for each treatment group on Day 28 and the percentage of participants with improvements (either "very much improved" or "much improved" on the PGIC scale) was reported for each treatment group.
|
Day 28
|
Percentage of Participants Reporting "Very Much Improved" or "Much Improved" According to the PGIC After 8 Weeks of Treatment (Day 56)
Time Frame: Day 56
|
The self-reported measure Patient's Global Impression of Change (PGIC) reflects a participant's belief about the efficacy of treatment.
PGIC is a 7-point scale depicting a patient's rating of overall improvement.
Participants rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
The counts and percentages of ordered responses to the participant's global perception of change were computed for each treatment group on Day 28 and the percentage of participants with improvements (either "very much improved" or "much improved" on the PGIC scale) was reported for each treatment group.
|
Day 56
|
Percentage of Participants Reporting "Very Much Improved" or "Much Improved" According to the PGIC at Day 85/Early Termination
Time Frame: Day 85/Early Termination
|
The self-reported measure Patient's Global Impression of Change (PGIC) reflects a participant's belief about the efficacy of treatment.
PGIC is a 7-point scale depicting a patient's rating of overall improvement.
Participants rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
The counts and percentages of ordered responses to the participant's global perception of change were computed for each treatment group on Day 28 and the percentage of participants with improvements (either "very much improved" or "much improved" on the PGIC scale) was reported for each treatment group.
|
Day 85/Early Termination
|
Percentage of Participants Rated as "Very Much Improved" or "Much Improved" by Clinicians According to the Clinician's Global Impression of Change (CGIC) at Day 85/Early Termination
Time Frame: Day 85/Early Termination
|
The Clinician's Global Impression of Change (CGIC) reflects a clinician's belief about the efficacy of treatment.
CGIC is a 7-point scale depicting a clinician's rating of a participant's overall improvement.
Clinicians rated the participant's change at Week 12 (Day 85) as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
The counts and percentages of ordered responses to the clinician's global perception of change were computed for each treatment group, and the percentage of participants rated by clinicians as having improvement (either "very much improved" or "much improved" on the CGIC scale) was reported for each treatment group.
|
Day 85/Early Termination
|
Acceptability Questionnaire: Percentage of Participants That Were Likely to Take Study Medication For At Least One Year
Time Frame: Day 85/Early Termination
|
At the end of the treatment period (Day 85), participants were asked "How likely would you be to take this medication?"
This question was asked in reference to the time frame of "At least one year".
The counts and percentages of ordered categorical responses to this question were computed for each treatment group.
|
Day 85/Early Termination
|
Acceptability Questionnaire: Percentage of Participants That Were Likely to Take Study Medication For At Least Six Months
Time Frame: Day 85/Early Termination
|
At the end of the treatment period (Day 85), participants were asked "How likely would you be to take this medication?"
This question was asked in reference to the time frame of "At least six months".
The counts and percentages of ordered categorical responses to this question were computed for each treatment group.
|
Day 85/Early Termination
|
Acceptability Questionnaire: Percentage of Participants That Were Likely to Take Study Medication For At Least Four Weeks
Time Frame: Day 85/Early Termination
|
At the end of the treatment period (Day 85), participants were asked "How likely would you be to take this medication?"
This question was asked in reference to the time frame of "At least four weeks".
The counts and percentages of ordered categorical responses to this question were computed for each treatment group.
|
Day 85/Early Termination
|
Acceptability Questionnaire: Percentage of Participants That Were Likely to Take Study Medication Twice Daily
Time Frame: Day 85/Early Termination
|
At the end of the treatment period (Day 85), participants were asked "How likely would you be to take this medication?"
This question was asked in reference to the time frame of "Twice daily".
The counts and percentages of ordered categorical responses to this question were computed for each treatment group.
|
Day 85/Early Termination
|
Taste Questionnaire: Percentage of Participants That Experienced Taste Effect After Taking Medication by Frequency After 12 Weeks of Treatment (Day 84)
Time Frame: Day 84
|
The tolerance to taste-related adverse events (AEs) was evaluated at the end of the study (Day 84) and a structured taste questionnaire was administered to participants experiencing a taste-related AE.
Participants were asked to indicate the frequency that they experienced the taste effect by answering the question "How frequently do you experience the taste effect after taking each dose of medication?"
The counts and percentages of categorical frequency responses to the individual items were computed for each treatment group.
|
Day 84
|
Taste Questionnaire: Percentage of Participants That Found Taste Effect of Study Medication Bothersome After 12 Weeks of Treatment (Day 84)
Time Frame: Day 84
|
The tolerance to taste-related adverse events (AEs) was evaluated at the end of the study (Day 84) and a structured taste questionnaire was administered to participants experiencing a taste-related AE to determine what degree the participant found the taste effect bothersome by answering the question "How bothersome is the taste effect of the medication?
The counts and percentages of categorical responses to the individual items were computed for each treatment group.
|
Day 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Afferent Pharmaceuticals Clinical Research, Afferent Pharmaceuticals, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nguyen AM, Schelfhout J, Muccino D, Bacci ED, La Rosa C, Vernon M, Birring SS. Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099737. doi: 10.1177/17534666221099737.
- Martin Nguyen A, Bacci ED, Vernon M, Birring SS, Rosa C, Muccino D, Schelfhout J. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743.
- Morice AH, Birring SS, Smith JA, McGarvey LP, Schelfhout J, Martin Nguyen A, Xu ZJ, Wu WC, Muccino DR, Sher MR. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung. 2021 Apr;199(2):121-129. doi: 10.1007/s00408-021-00437-7. Epub 2021 Apr 7.
- Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2015
Primary Completion (Actual)
October 31, 2016
Study Completion (Actual)
November 4, 2016
Study Registration Dates
First Submitted
November 20, 2015
First Submitted That Met QC Criteria
November 23, 2015
First Posted (Estimate)
November 24, 2015
Study Record Updates
Last Update Posted (Actual)
June 30, 2020
Last Update Submitted That Met QC Criteria
June 17, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7264-012
- AF219-012 (Other Identifier: Afferent Pharmaceuticals)
- 2015-005064-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Chronic Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Bellus Health Inc. - a GSK companyRecruitingRefractory Chronic CoughKorea, Republic of, United States, Taiwan, Australia, New Zealand, Czechia, United Kingdom, Germany, Slovakia, India
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Bellus Health IncTerminatedChronic Refractory CoughUnited States, United Kingdom
-
University Hospital, ToulouseMSD FranceActive, not recruitingRefractory Chronic CoughFrance
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.Completed
-
The First Affiliated Hospital of Guangzhou Medical...Unknown
-
Patara PharmaCompletedRefractory Chronic CoughNetherlands, United Kingdom
-
Beijing Tide Pharmaceutical Co., LtdNot yet recruitingRefractory Chronic Cough
Clinical Trials on Placebo (for gefapixant)
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.Completed
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedChronic CoughUnited States, Argentina, Canada, Czechia, Denmark, France, Hungary, Israel, Japan, Korea, Republic of, Peru, Poland, Spain, Taiwan, Turkey, Ukraine, United Kingdom
-
Merck Sharp & Dohme LLCCompletedChronic CoughUnited States, Argentina, Colombia, Germany, Guatemala, Israel, Korea, Republic of, Peru, Russian Federation, Spain, Ukraine, United Kingdom
-
Merck Sharp & Dohme LLCCompletedChronic CoughColombia, Guatemala, Korea, Republic of, Peru, Ukraine, United Kingdom, United States, Canada, Germany, Poland, Russian Federation, Spain
-
Merck Sharp & Dohme LLCCompletedObstructive Sleep Apnea (OSA)United States, Belgium
-
Merck Sharp & Dohme LLCTerminated